Skip to main content
Erschienen in: Familial Cancer 4/2010

01.12.2010

Real world experience with cancer genetic counseling via telephone

verfasst von: Rebecca Sutphen, Barbara Davila, Heather Shappell, Tricia Holtje, Susan Vadaparampil, Sue Friedman, Michele Toscano, Joanne Armstrong

Erschienen in: Familial Cancer | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

One barrier to genetic testing is the lack of access to genetic counselors. We provided cancer genetic counseling via telephone, through a pilot project for employees of a national health insurer, Aetna, Inc. Knowledge transfer, behavioral intentions, and patient satisfaction were assessed by survey after genetic counseling. Aetna sent an individual email to its employees nationwide notifying them of the availability of a new telephone genetic counseling and testing program and providing a link to take a brief screening questionnaire to determine whether they may be at risk of hereditary cancer. Employees completing the questionnaire received immediate feedback regarding whether there appeared to be a risk of hereditary cancer. If so, they were invited to schedule a telephonic genetic counseling session. After the session, respondents completed an online survey. 397 individuals completed the questionnaire. 39 proceeded with telephone genetic counseling, and 22 completed the follow-up survey, including all 11 women with family history warranting genetic testing. One third reported prior discussion about inherited cancer risk with their primary care provider (PCP); 12% were referred to a geneticist; 20% had an accurate perception of their own cancer risk. After counseling, 94% reported understanding their risk for cancer and 87% were aware of available risk-reduction strategies. 87% of high-risk respondents intended to engage in risk-management interventions. 93% reported high satisfaction. 66% indicated they would not have pursued genetic counseling if it had not been available by phone. Results suggest telephone counseling is a viable option for increasing access to genetic experts. In this sample, telephone counseling increases knowledge of cancer risk, motivates intention to change health-related behaviors, and elicits a high satisfaction level. Consequently, Aetna now offers telephone cancer genetic counseling nationwide as a covered benefit.
Literatur
1.
Zurück zum Zitat National Comprehensive Cancer Network Cancer Guidelines for Patients and Physicians by Cancer Experts, 2010 National Comprehensive Cancer Network Cancer Guidelines for Patients and Physicians by Cancer Experts, 2010
2.
Zurück zum Zitat Women’s Health: Issues Surrounding Cancer Risk Assessment for Hereditary Breast and Ovarian Cancer and BRCA 1/2 Genetic Testing, Research Forum of the Society of Women’s Health Research White Paper, 2007 Women’s Health: Issues Surrounding Cancer Risk Assessment for Hereditary Breast and Ovarian Cancer and BRCA 1/2 Genetic Testing, Research Forum of the Society of Women’s Health Research White Paper, 2007
3.
Zurück zum Zitat Elements of Cancer Genetics Risk Assessment and Counseling, National Cancer Institute, U.S. Nationals Institutes of Health, 2008 Elements of Cancer Genetics Risk Assessment and Counseling, National Cancer Institute, U.S. Nationals Institutes of Health, 2008
4.
Zurück zum Zitat Helmes AW, Culver JO, Bowen DJ (2006) Results of a randomized study of telephone versus in-person breast cancer risk counseling. Patient Educ Couns 64:96–103CrossRefPubMed Helmes AW, Culver JO, Bowen DJ (2006) Results of a randomized study of telephone versus in-person breast cancer risk counseling. Patient Educ Couns 64:96–103CrossRefPubMed
5.
Zurück zum Zitat Peshkin BN, Demarco TA, Graves KD et al (2008) Telephone genetic counseling for high-risk women undergoing BRCA1 and BRCA2 testing: rationale and development of a randomized controlled trial. Genet Test 12:37–52CrossRefPubMed Peshkin BN, Demarco TA, Graves KD et al (2008) Telephone genetic counseling for high-risk women undergoing BRCA1 and BRCA2 testing: rationale and development of a randomized controlled trial. Genet Test 12:37–52CrossRefPubMed
6.
Zurück zum Zitat Baumanis L, Evans JP, Callanan N et al (2009) Telephoned BRCA1/2 genetic test results: prevalence, practice, and patient satisfaction. J Genet Couns 18:447–463CrossRefPubMed Baumanis L, Evans JP, Callanan N et al (2009) Telephoned BRCA1/2 genetic test results: prevalence, practice, and patient satisfaction. J Genet Couns 18:447–463CrossRefPubMed
7.
Zurück zum Zitat Aetna At-A-Glance (2007) Aetna facts. Aetna, Inc, Hartford Aetna At-A-Glance (2007) Aetna facts. Aetna, Inc, Hartford
8.
Zurück zum Zitat Wideroff L, Freedman AN, Olson L et al (2003) Physician use of genetic testing for cancer susceptibility: results of a national survey. Cancer Epidemiol Biomarkers Prev 12:295–303PubMed Wideroff L, Freedman AN, Olson L et al (2003) Physician use of genetic testing for cancer susceptibility: results of a national survey. Cancer Epidemiol Biomarkers Prev 12:295–303PubMed
9.
Zurück zum Zitat Evans DG, Burnell LD, Hopwood P et al (1993) Perception of risk in women with a family history of breast cancer. Br J Cancer 67:612–614PubMed Evans DG, Burnell LD, Hopwood P et al (1993) Perception of risk in women with a family history of breast cancer. Br J Cancer 67:612–614PubMed
10.
Zurück zum Zitat Ormond K, Haun J, Cook L et al (2000) Recommendations for Telephone Counseling. J Genet Couns 9 Ormond K, Haun J, Cook L et al (2000) Recommendations for Telephone Counseling. J Genet Couns 9
11.
Zurück zum Zitat Genetic Information Nondiscrimination Act of 2008, National Human Genome Research Institute, National Institutes of Health, 2008 Genetic Information Nondiscrimination Act of 2008, National Human Genome Research Institute, National Institutes of Health, 2008
12.
Zurück zum Zitat Myriad Genetic Laboratories, Inc., 2008 Myriad Genetic Laboratories, Inc., 2008
Metadaten
Titel
Real world experience with cancer genetic counseling via telephone
verfasst von
Rebecca Sutphen
Barbara Davila
Heather Shappell
Tricia Holtje
Susan Vadaparampil
Sue Friedman
Michele Toscano
Joanne Armstrong
Publikationsdatum
01.12.2010
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 4/2010
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-010-9369-y

Weitere Artikel der Ausgabe 4/2010

Familial Cancer 4/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.